Vanguard Group Inc Brooklyn Immuno Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.23 - $0.71 $58,337 - $180,085	-253,642 Reduced 22.23%	887,228 $220,000
Q2 2022 Aug 12, 2022	SELL	$0.48 - $2.03 $71,098 - $300,685	-148,121 Reduced 11.49%	1,140,870 $590,000
Q1 2022 May 13, 2022	SELL	$1.76 - $4.84 $37,838 - $104,055	-21,499 Reduced 1.64%	1,288,991 $2.64 Million
Q4 2021 Feb 14, 2022	BUY	$4.17 - $9.79 $3.2 Million - $7.51 Million	766,651 Added 140.97%	1,310,490 $5.47 Million
Q3 2021 Nov 12, 2021	BUY	$8.86 - $17.05 $1.19 Million - $2.3 Million	134,741 Added 32.94%	543,839 $5.06 Million
Q2 2021 Aug 13, 2021	BUY	$3.75 - $78.5 $1.53 Million - $32.1 Million	409,098 New	409,098 $7.37 Million

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.